A Brief Review of Analytical Methods for the Estimation of Brivaracetam in Pharmaceutical Formulation and Biological Matrices
Main Article Content
Abstract
Partial-onset seizures are treated with Brivaracetam, which is a chemical butanamide derivative. Brivaracetam (BRV) in pharmaceutical and biological samples can be determined using various analytical techniques, including HPLC, UV-visible, and hybrid techniques including LC-MS, LC-MS/MS, UPLC-MS/MS, & other techniques, all of which are discussed in this review article. The review will analyze BRV determination using a variety of analytical approaches in comparison with each other. The findings of this review paper can be used as a starting point for future analysis of BRV.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Deepali B. Stability Indicating Thin-Layer Chromatographic Determination of Brivarecetam as Bulk Drug: Application to Forced Degradation Study. Int J PharmTech Res [Internet]. 2018 [cited 2021 Jun 25];11(4):351–60. Available from: http://dx.doi.org/10.20902/IJPTR.2018.11406 DOI: https://doi.org/10.20902/IJPTR.2018.11406
Fan L, Zhang W, Yin M, Zhang T, Wu X, Zhang H, et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol (Madr). 2012 Apr;51(4):473–9. DOI: https://doi.org/10.3109/0284186X.2011.648338
Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol [Internet]. 2008 Aug 26 [cited 2022 Apr 18];154(8):1555. Available from: /pmc/articles/PMC2518467/ DOI: https://doi.org/10.1038/bjp.2008.221
Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep [Internet]. 2008 [cited 2022 Apr 18];8(4):345–52. Available from: https://pubmed.ncbi.nlm.nih.gov/18590620/ DOI: https://doi.org/10.1007/s11910-008-0053-7
Brivaracetam | C11H20N2O2 - PubChem [Internet]. [cited 2021 Jun 25]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Brivaracetam
Alekhya C, Teddu S, Lakshmi BVS. Briviact-A Review. Indo Am J Pharm. 2016;3:1068–73.
Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar 1;76(4):517–22. DOI: https://doi.org/10.1007/s40265-016-0555-6
Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168. DOI: https://doi.org/10.1016/j.neuropharm.2020.107966
Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008 Jul;66(1):71–5. DOI: https://doi.org/10.1111/j.1365-2125.2008.03158.x
von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics [Internet]. 2007 Jan [cited 2022 Apr 18];4(1):84. Available from: /pmc/articles/PMC7479692/ DOI: https://doi.org/10.1016/j.nurt.2006.11.004
Malawska B, Kulig K. Brivaracetam: A new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs. 2008 Mar;17(3):361–9. DOI: https://doi.org/10.1517/13543784.17.3.361
Rogawski MA. A New SV2A Ligand for Epilepsy. Cell. 2016;167:587. DOI: https://doi.org/10.1016/j.cell.2016.09.057
Iqbal M, Ezzeldin E, Al-Rashood KA. UPLC–MS/MS assay for identification and quantification of brivaracetam in plasma sample: Application to pharmacokinetic study in rats. J Chromatogr B Anal Technol Biomed Life Sci. 2017 Aug 15;1060:63–70. DOI: https://doi.org/10.1016/j.jchromb.2017.05.039
Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al. A selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action, Epilepsia. Off J Int Leag against Epilepsy. 2016;57:201–9. DOI: https://doi.org/10.1111/epi.13267
Pasha SI, Varanasi MB, Mohammed I. Chromogenic spectrophotometric estimation of Brivaracetam in bulk drug and it’s formulation with Folin Ciocalteu reagent. IOSR J Pharm. 2017;7:44–8.
Mansour NM, El-Sherbiny DT, Ibrahim FA, El Subbagh HI. Development of an Inexpensive, sensitive and green HPLC method for the simultaneous determination of brivaracetam, piracetam and carbamazepine; application to pharmaceuticals and human plasma. Microchem J. 2021 Apr 1;163:105863.
Mali N V., Mhaske D V. HPLC Studies on degradation behaviour of Brivaracetam and development of validated stability-indicating HPLC Assay method. Int J Sci Res Methodol. 2016;4:43–57.
Choppari T, Gunnam S, Chennuru LN, Cherla PM, Talluri MVNK. Evaluation of Chiral Liquid Chromatographic Method for Separation and Quantification of Isomers of Brivaracetam. J Chromatogr Sci [Internet]. 2022 Mar 23 [cited 2022 Apr 18];60(3):250–9. Available from: DOI: https://doi.org/10.1093/chromsci/bmab075
https://pubmed.ncbi.nlm.nih.gov/34173643/
Bhamare P, Dubey R, Upmanyu N, Natarajan S, Umadoss P. A rapid liquid chromatographic estimation of Brivaracetam and it’s related impuritie. Asian J Pharm Res. 2019;9:14–24.
Vishweshwar V, Babu JM, Muralikrishna R. Development and validation of stability-indicating UPLC method for the determination of brivaracetam, its related impurities and degradation products. Int J Pharma Sci Res. 2018;9:2315–27.
Spandana KVLD, Subhashini NJP. Analytical Method Development and Validation of Brivaracetam In Bulk And Pharmaceutical Dosage Form By RP-HPLC Method. IOSR J Pharm [Internet]. 2021 [cited 2022 Apr 18];11:26–33. Available from: www.iosrphr.org
Mansour NM, El-Sherbiny DT, Ibrahim FA, El Subbagh HI. Development of an Inexpensive, sensitive and green HPLC method for the simultaneous determination of brivaracetam, piracetam and carbamazepine; application to pharmaceuticals and human plasma. Microchem J. 2021 Apr 1;163:105863. DOI: https://doi.org/10.1016/j.microc.2020.105863
Bhamare P, Umadoss P, Upmanyu N, Dubey R. Identification, isolation, structural characterisation, synthesis and: In silico toxicity prediction of the alkaline hydrolytic degradation product of brivaracetam by using LC-PDA, preparative HPLC, LC/HESI/LTQ, FTIR, and 1H NMR. Anal Methods [Internet]. 2020 Apr 14 [cited 2021 Jun 25];12(14):1868–81.Availablefrom: https://pubs.rsc.org/en/content/articlehtml/2020/ay/c9ay02582k
Vasanth DA, Rajkamal B. A VALIDATED LC-MS/MS METHOD FOR PHARMACOKINETIC STUDY OF BRIVARACETAM IN HEALTHY RABBITS. Int J Pharm Pharm Sci [Internet]. 2018 Feb 1 [cited 2021 Jun 25];10(2):24. Available from: http://creativecommons.org/licenses/by/4.0/ DOI: https://doi.org/10.22159/ijpps.2018v10i2.21457
Mohamed S, Riva R, Contin M. Development and Validation of an UHPLC-MS/MS Assay for the Therapeutic Monitoring of Brivaracetam Plasma Concentrations in Patients with Epilepsy. Ther Drug Monit [Internet]. 2020 Jun 1 [cited 2021 Jun 25];42(3):445–51. Available from: DOI: https://doi.org/10.1097/FTD.0000000000000726
https://pubmed.ncbi.nlm.nih.gov/31934942/
Palakeeti B, Reddy KV, Gobi KV, Rao PN, Chinta JP. Simple and efficient method for the quantification of antiepileptic drugs in human plasma by using magnetic graphene oxide-β-cyclodextrin composite as a sorbent. Futur J Pharm Sci [Internet]. 2021;7(1). Available from: https://doi.org/10.1186/s43094-021-00239-x DOI: https://doi.org/10.1186/s43094-021-00239-x
Bhamare P, Umadoss P, Upmanyu N, Dubey R. Identification, isolation, structural characterisation, synthesis and in silico toxicity prediction of the alkaline hydrolytic degradation product of brivaracetam by using LC-PDA, preparative HPLC, LC/HESI/LTQ, FTIR, and 1H NMR. Anal Methods [Internet]. 2020 Apr 9 [cited 2022Apr18];12(14):1868–81.Availablefrom:https://pubs.rsc.org/en/content/articlehtml/2020/ay/c9ay02582k DOI: https://doi.org/10.1039/C9AY02582K